Search Results

There are 8191758 results for: content related to: Olanzapine treatment for dopaminergic-induced hallucinations

  1. You have free access to this content
    Olanzapine: Preclinical and Clinical Profiles of a Novel Antipsychotic Agent

    CNS Drug Reviews

    Volume 6, Issue 4, December 2000, Pages: 303–363, Gary D. Tollefson and Cindy C. Taylor

    Version of Record online : 7 JUN 2006, DOI: 10.1111/j.1527-3458.2000.tb00155.x

  2. Olanzapine alone or in combination for acute mania

    Intervention Review

    The Cochrane Library

    Jennifer M Rendell, Harm J Gijsman, Paul K Keck, Guy Goodwin and John Geddes

    Published Online : 20 JAN 2003, DOI: 10.1002/14651858.CD004040

  3. Olanzapine versus other atypical antipsychotics for schizophrenia

    Intervention Review

    The Cochrane Library

    Katja Komossa, Christine Rummel-Kluge, Heike Hunger, Franziska Schmid, Sandra Schwarz, Lorna Duggan, Werner Kissling and Stefan Leucht

    Published Online : 17 MAR 2010, DOI: 10.1002/14651858.CD006654.pub2

  4. Olanzapine in long-term treatment for bipolar disorder

    Intervention Review

    The Cochrane Library

    Andrea Cipriani, Jennifer M Rendell and John Geddes

    Published Online : 21 JAN 2009, DOI: 10.1002/14651858.CD004367.pub2

  5. Olanzapine in Treatment for Bipolar Disorder

    Bipolar Psychopharmacotherapy: Caring for the Patient, Second Edition

    Mauricio Tohen, Giedra Campbell, Juan-Carlos Gómez, Pages: 79–107, 2011

    Published Online : 13 APR 2011, DOI: 10.1002/9780470975114.ch6

  6. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses

    Intervention Review

    The Cochrane Library

    Ravindra B Belgamwar and Mark Fenton

    Published Online : 20 APR 2005, DOI: 10.1002/14651858.CD003729.pub2

  7. Olanzapine for schizophrenia

    Intervention Review

    The Cochrane Library

    Lorna Duggan, Mark Fenton, John Rathbone, Roland Dardennes, Ahmed El-Dosoky and Saroja Indran

    Published Online : 20 APR 2005, DOI: 10.1002/14651858.CD001359.pub2

  8. Characterization of olanzapine (LY170053) in human liver slices by liquid chromatography/tandem mass spectrometry

    Journal of Mass Spectrometry

    Volume 33, Issue 12, December 1998, Pages: 1237–1245, A. T. Murphy, B. G. Lake, J. R. Bernstein, R. B. Franklin and T. A. Gillespie

    Version of Record online : 5 JAN 1999, DOI: 10.1002/(SICI)1096-9888(199812)33:12<1237::AID-JMS742>3.0.CO;2-F

  9. You have free access to this content
    Hormonal and Metabolic Effects of Olanzapine and Clozapine Related to Body Weight in Rodents

    Obesity

    Volume 14, Issue 1, January 2006, Pages: 36–51, Vance L. Albaugh, Cathy R. Henry, Nicholas T. Bello, Andras Hajnal, Susan L. Lynch, Beth Halle and Christopher J. Lynch

    Version of Record online : 6 SEP 2012, DOI: 10.1038/oby.2006.6

  10. You have full text access to this OnlineOpen article
    Antipsychotics inhibit glucose transport: Determination of olanzapine binding site inStaphylococcus epidermidis glucose/H+ symporter

    FEBS Open Bio

    Volume 5, Issue 1, January 01, 2015, Pages: 335–340, Petr Babkin, Alayna M. George Thompson, Cristina V. Iancu, D. Eric Walters and Jun-yong Choe

    Version of Record online : 15 APR 2015, DOI: 10.1016/j.fob.2015.04.006

  11. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease

    Intervention Review

    The Cochrane Library

    Clive G Ballard, Jonathan Waite and Jacqueline Birks

    Published Online : 25 JAN 2006, DOI: 10.1002/14651858.CD003476.pub2

  12. Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3

    Human Psychopharmacology: Clinical and Experimental

    Volume 31, Issue 2, March 2016, Pages: 83–92, Maho Okubo, Momoko Narita, Norie Murayama, Youichi Akimoto, Akiko Goto and Hiroshi Yamazaki

    Version of Record online : 8 FEB 2016, DOI: 10.1002/hup.2515

  13. Clozapine versus other atypical antipsychotics for schizophrenia

    Intervention Review

    The Cochrane Library

    Claudia Asenjo Lobos, Katja Komossa, Christine Rummel-Kluge, Heike Hunger, Franziska Schmid, Sandra Schwarz and Stefan Leucht

    Published Online : 10 NOV 2010, DOI: 10.1002/14651858.CD006633.pub2

  14. You have free access to this content
    Olanzapine pamoate: a stick in time?

    International Journal of Clinical Practice

    Volume 63, Issue 1, January 2009, Pages: 140–150, L. Citrome

    Version of Record online : 1 OCT 2008, DOI: 10.1111/j.1742-1241.2008.01900.x

  15. Pharmacokinetics and tissue distribution of olanzapine in rats

    Biopharmaceutics & Drug Disposition

    Volume 20, Issue 8, November 1999, Pages: 369–377, Manickam Aravagiri, Yaroslav Teper and Stephen R. Marder

    Version of Record online : 22 JUN 2000, DOI: 10.1002/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2-6

  16. Olanzapine in Treatment for Bipolar Disorder

    Bipolar Psychopharmacotherapy: Caring for the Patient

    Mauricio Tohen, Giedra Campbell, Daniel Lin, Pages: 85–103, 2006

    Published Online : 31 MAY 2006, DOI: 10.1002/0470017953.ch6

  17. Pharmacological interventions for borderline personality disorder

    Intervention Review

    The Cochrane Library

    Jutta Stoffers, Birgit A Völlm, Gerta Rücker, Antje Timmer, Nick Huband and Klaus Lieb

    Published Online : 16 JUN 2010, DOI: 10.1002/14651858.CD005653.pub2

  18. Olanzapine-induced early cardiovascular effects are mediated by the biological clock and prevented by melatonin

    Journal of Pineal Research

    Volume 62, Issue 4, May 2017, Francisco Romo-Nava, Frederik N. Buijs, Marcela Valdés-Tovar, Gloria Benítez-King, MariCarmen Basualdo, Mercedes Perusquía, Gerhard Heinze, Carolina Escobar and Ruud M. Buijs

    Version of Record online : 15 MAR 2017, DOI: 10.1111/jpi.12402

  19. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia

    International Journal of Geriatric Psychiatry

    Volume 18, Issue 5, May 2003, Pages: 432–440, C. W. Ritchie, E. Chiu, S. Harrigan, K. Hall, A. Hassett, S. Macfarlane, M. Mastwyk, D. W. O'Connor, J. Opie and D. Ames

    Version of Record online : 9 MAY 2003, DOI: 10.1002/gps.862

  20. Olanzapine increases hepatic glucose production through the activation of hypothalamic adenosine 5′-monophosphate-activated protein kinase

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 12, December 2013, Pages: 1128–1135, M. Ikegami, H. Ikeda, T. Ohashi, M. Ohsawa, Y. Ishikawa, M. Kai, A. Kamei and J. Kamei

    Version of Record online : 11 JUL 2013, DOI: 10.1111/dom.12148